Abstract:Deubiquitinases (DUBs) play important roles in various human cancers and targeting DUBs is considered as a novel anticancer therapeutic strategy. Overexpression of ubiquitin specific protease 7 and 22 (USP7 and USP22) are associated with malignancy, therapy resistance, and poor prognosis in many cancers. Although both DUBs are involved in the regulation of similar genes and signaling pathways, such as histone H2B monoubiquitination (H2Bub1), c-Myc, FOXP3, and p53, the interdependence of USP22 and USP7 expression has never been described. In the study, we found that targeting USP7 via either siRNA-mediated knockdown or pharmaceutical inhibitors dramatically upregulates USP22 in cancer cells. Mechanistically, the elevated USP22 occurs through a transcriptional pathway, possibly due to desuppression of the transcriptional activity of SP1 via promoting its degradation upon USP7 inhibition. Importantly, increased USP22 expression leads to significant activation of downstream signal pathways including H2Bub1 and c-Myc, which may potentially enhance cancer malignancy and counteract the anticancer efficacy of USP7 inhibition. Importantly, targeting USP7 further suppresses the in vitro proliferation of USP22-knockout (USP22-Ko) A549 and H1299 lung cancer cells and induces a stronger activation of p53 tumor suppressor signaling pathway. In addition, USP22-Ko cancer cells are more sensitive to a combination of cisplatin and USP7 inhibitor. USP7 inhibitor treatment further suppresses in vivo angiogenesis and tumor growth and induced more apoptosis in USP22-Ko cancer xenografts. Taken together, our findings demonstrate that USP7 inhibition can dramatically upregulate USP22 in cancer cells; and targeting USP7 and USP22 may represent a more effective approach for targeted cancer therapy, which warrants further study.

Ubiquitin-Specific Peptidase 7: A Novel Deubiquitinase That Regulates Protein Homeostasis and Cancers

USP7: Target Validation and Drug Discovery for Cancer Therapy

Ubiquitin-specific peptidase 22 in cancer

Targeting Ubiquitin Specific Protease 7 in Cancer: A Deubiquitinase with Great Prospects

The emerging nature of Ubiquitin-specific protease 7 (USP7): a new target in cancer therapy

Recent Insights into USP7: Construct, Pathophysiology, and Inhibitors

USP15 in Cancer and Other Diseases: From Diverse Functionsto Therapeutic Targets

Targeting Ubiquitin-Specific Protease 7 (USP7) in Cancer: A New Insight to Overcome Drug Resistance

Ubiquitin specific peptidase 3: an emerging deubiquitinase that regulates physiology and diseases

USP10 as a Potential Therapeutic Target in Human Cancers

Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development

USP32 deubiquitinase: cellular functions, regulatory mechanisms, and potential as a cancer therapy target

The emerging role of USP29 in cancer and other diseases

Ubiquitin-Specific Proteases: Players in Cancer Cellular Processes

USP7 Substrates Identified by Proteomics Analysis Reveal the Specificity of USP7.

Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors

Advances in research on a novel anticancer target USP7 and its inhibitors

The Dual Role of USP11 in Cancer

The Oncogenic Role Of Ubiquitin Specific Peptidase (Usp8) And Its Signaling Pathways Targeting For Cancer Therapeutics

Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells

Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy